Literature DB >> 30863952

Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?

Naomi Lange1,2, Jean-François Dufour3,4.   

Abstract

The prognosis of patients with hepatocellular carcinoma is dependent on the stage of tumor at diagnosis. The earlier the tumor is found, the higher the chances to offer a curative treatment. In order to diagnose hepatocellular carcinoma early, patients at risk should be enrolled in a surveillance program. The population at risk is usually defined as patients with cirrhosis. These patients should have twice a year a ultrasonographic examination of the liver. However, more and more patients will develop hepatocellular carcinoma in the context of nonalcoholic fatty liver disease which is tightly linked to obesity and diabetes. In these patients, this approach is jeopardized by the difficulty to perform a sonography of good quality due to the obesity and more importantly by the fact that hepatocellular carcinoma occurs frequently in the context of nonalcoholic fatty liver disease before the cirrhosis. This article reviews the impact of the changing epidemiology of hepatocellular carcinoma on its screening.

Entities:  

Keywords:  Epidemiology; Hepatocellular carcinoma; Liver cancer; Population at risk; Surveillance

Mesh:

Year:  2019        PMID: 30863952     DOI: 10.1007/s10620-019-05515-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  79 in total

1.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.

Authors:  George N Ioannou; Pamela K Green; Lauren A Beste; Elijah J Mun; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

Review 2.  Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies.

Authors:  F Turati; C Galeone; M Rota; C Pelucchi; E Negri; V Bagnardi; G Corrao; P Boffetta; C La Vecchia
Journal:  Ann Oncol       Date:  2014-03-14       Impact factor: 32.976

3.  Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.

Authors:  Jung Hee Kim; Dong Hyun Sinn; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

4.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Authors:  Charlotte E Costentin; Richard Layese; Valérie Bourcier; Carole Cagnot; Patrick Marcellin; Dominique Guyader; Stanislas Pol; Dominique Larrey; Victor De Lédinghen; Denis Ouzan; Fabien Zoulim; Dominique Roulot; Albert Tran; Jean-Pierre Bronowicki; Jean-Pierre Zarski; Ghassan Riachi; Paul Calès; Jean-Marie Péron; Laurent Alric; Marc Bourlière; Philippe Mathurin; Jean-Frédéric Blanc; Armand Abergel; Lawrence Serfaty; Ariane Mallat; Jean-Didier Grangé; Pierre Attali; Yannick Bacq; Claire Wartelle; Thông Dao; Dominique Thabut; Christophe Pilette; Christine Silvain; Christos Christidis; Eric Nguyen-Khac; Brigitte Bernard-Chabert; David Zucman; Vincent Di Martino; Angela Sutton; Eric Letouzé; Sandrine Imbeaud; Jessica Zucman-Rossi; Etienne Audureau; Françoise Roudot-Thoraval; Pierre Nahon
Journal:  Gastroenterology       Date:  2018-05-03       Impact factor: 22.682

6.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Authors:  Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman
Journal:  Gastroenterology       Date:  2008-09-18       Impact factor: 22.682

7.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Peter Richardson; Jennifer Kramer
Journal:  Hepatology       Date:  2016-04-19       Impact factor: 17.425

8.  Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.

Authors:  Manal M Hassan; Lu-Yu Hwang; Chiq J Hatten; Mark Swaim; Donghui Li; James L Abbruzzese; Palmer Beasley; Yehuda Z Patt
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

9.  Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.

Authors:  Bashar Mohamad; Vaishal Shah; Mykola Onyshchenko; Mohammed Elshamy; Federico Aucejo; Rocio Lopez; Ibrahim A Hanouneh; Razan Alhaddad; Naim Alkhouri
Journal:  Hepatol Int       Date:  2015-11-11       Impact factor: 6.047

10.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

View more
  5 in total

1.  Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1.

Authors:  Jian Pu; Xianjian Wu; Yi Wu; Zesheng Shao; Chunying Luo; Qianli Tang; Jianchu Wang; Huamei Wei; Yuan Lu
Journal:  Aging (Albany NY)       Date:  2021-03-22       Impact factor: 5.682

2.  Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

Authors:  Chun-Ming Ho; Kuen-Tyng Lin; Roger Shen; De-Leung Gu; Szu-Shuo Lee; Wen-Hui Su; Yuh-Shan Jou
Journal:  Comput Struct Biotechnol J       Date:  2022-04-09       Impact factor: 6.155

3.  Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy.

Authors:  Xu Wang; Yunfei Chen; Ke Dong; Yujing Ma; Qizhi Jin; Shujun Yin; Xiaoshi Zhu; Shan Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-10       Impact factor: 8.886

4.  The effects of fructose and metabolic inhibition on hepatocellular carcinoma.

Authors:  Brittany Dewdney; Mohammed Alanazy; Rhys Gillman; Sarah Walker; Miriam Wankell; Liang Qiao; Jacob George; Alexandra Roberts; Lionel Hebbard
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

5.  LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability.

Authors:  Heng Liu; Dongming Li; Ling Zhou; Shuang Kan; Guozhang He; Kun Zhou; Liping Wang; Ming Chen; Wei Shu
Journal:  J Cell Mol Med       Date:  2020-09-08       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.